ASTREA PHARMA Trademark

Trademark Overview

On Wednesday, January 19, 2022, a trademark application was filed for ASTREA PHARMA with the United States Patent and Trademark Office. The USPTO has given the ASTREA PHARMA trademark a serial number of 97227927. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Monday, September 1, 2025. This trademark is owned by Astrea SA. The ASTREA PHARMA trademark is filed in the Treatment & Processing of Materials Services category with the following description:

Custom manufacture of pharmaceuticals, namely, custom manufacture of finished dose pharmaceutical preparations in oral solid dose and sterile injectable form for biopharmaceutical companies
astrea pharma

General Information

Serial Number97227927
Word MarkASTREA PHARMA
Filing DateWednesday, January 19, 2022
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateMonday, September 1, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing5 - Drawing with word(s) / letter(s) / number(s) in Stylized form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesCustom manufacture of pharmaceuticals, namely, custom manufacture of finished dose pharmaceutical preparations in oral solid dose and sterile injectable form for biopharmaceutical companies
Description of MarkThe mark consists of the term ASTREA in a stylized font above the term PHARMA in a stylized font.
Indication of Colors claimedColor is not claimed as a feature of the mark.
NOT AVAILABLE"PHARMA"

Classification Information

International Class040 - Treatment of materials.
US Class Codes100, 103, 106
Class Status Code6 - Active
Class Status DateTuesday, January 25, 2022
Primary Code040
First Use Anywhere DateFriday, January 31, 2020
First Use In Commerce DateFriday, January 31, 2020

Trademark Owner History

Party NameAstrea SA
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressLuxembourg L-1468
LU

Trademark Events

Event DateEvent Description
Saturday, January 22, 2022NEW APPLICATION ENTERED
Tuesday, January 25, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, October 27, 2022ASSIGNED TO EXAMINER
Friday, October 28, 2022NON-FINAL ACTION WRITTEN
Friday, October 28, 2022NON-FINAL ACTION E-MAILED
Friday, October 28, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, February 27, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, February 27, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, February 28, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, May 1, 2023SUSPENSION LETTER WRITTEN
Monday, May 1, 2023LETTER OF SUSPENSION E-MAILED
Monday, May 1, 2023NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Wednesday, January 3, 2024SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Monday, January 27, 2025NON-FINAL ACTION E-MAILED
Monday, January 27, 2025NON-FINAL ACTION WRITTEN
Sunday, January 28, 2024SUSPENSION LETTER WRITTEN
Sunday, January 28, 2024LETTER OF SUSPENSION E-MAILED
Sunday, January 28, 2024NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Wednesday, January 8, 2025SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Monday, January 27, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, April 3, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, April 3, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, April 3, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, May 15, 2025FINAL REFUSAL WRITTEN
Thursday, May 15, 2025FINAL REFUSAL E-MAILED
Thursday, May 15, 2025NOTIFICATION OF FINAL REFUSAL EMAILED
Monday, September 1, 2025ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Monday, September 1, 2025ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE

Related Keywords

pharma astrea custom dose manufacture injectable sterile form companies biopharmaceutical solid preparations